U.S. Contraceptive Market Size

The U.S. Contraceptive Market size was valued at USD  8,906.4 million in 2024 and is poised to grow from USD  9,226.0 million in 2025 to USD 12,423.5 million by 2032, at a CAGR of 4.7% over the forecast period (2025- 2032).       

The U.S. contraceptive market is highly competitive, with a diverse range of products and key players. The market is primarily driven by the growing awareness of reproductive health and increasing adoption of long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and implants. Prominent players like Bayer AG, Johnson & Johnson, and Pfizer dominate with a strong product portfolio that includes oral contraceptives, condoms, and hormonal devices. The market also sees rising competition from newer entrants offering innovative products like non-hormonal contraceptives, emergency contraceptive pills, and male contraceptives, gaining traction due to shifting consumer preferences for alternatives. Additionally, strategic collaborations and product launches, such as Bayer’s IUD advancements and innovative contraceptive pills by HRA Pharma, further intensify competition. The regulatory landscape, evolving consumer demands, and ongoing investments in R&D are expected to shape the competitive dynamics, with companies focusing on accessibility, affordability, and sustainability. 'Merck & Co., Inc', 'Teva Pharmaceutical Industries Ltd.', 'Bayer AG', 'HLL Lifecare Ltd', 'Viatris', 'Amneal Pharmaceuticals', 'The Population Council', 'AbbVie Inc.', 'Johnson & Johnson (J&J)', 'Mayer Laboratories, Inc.', 'Apothecus Pharmaceutical Corporation', 'Medicines360', 'Reckitt Benckiser', 'Piramal Healthcare', 'Laboratoires Majorelle', 'Mithra Pharmaceuticals SA', 'Organon', 'Daré Bioscience, Inc', 'Pregna International Ltd', 'In September 2024, CooperSurgical introduced a new single-hand inserter for its Paragard® Intrauterine Copper Contraceptive, which has recently received FDA approval. This innovation streamlines the insertion process, making it more accessible for both healthcare providers and patients. Paragard, a hormone-free IUD with over 30 years of clinical history, provides more than 99% efficacy for up to 10 years and offers immediate reversibility. A 2023 survey revealed that 91% of users aged 25-50 expressed satisfaction with the product. The newly available inserter features an intuitive design, enhancing convenience while maintaining the product’s reliability.', 'In March 2024, Perrigo Company announced that the U.S. FDA has granted approval for Opill®, the first-ever over-the-counter (OTC) progestin-only daily oral contraceptive, suitable for all age groups. This landmark approval seeks to enhance access to contraception, addressing a crucial gap, as 45% of pregnancies in the U.S. are unintended. Backed by leading medical organizations, Opill® is recognized as a safe and effective pregnancy prevention method. The product is set to be available both online and in stores by early 2024, marking a significant advancement in women's health and empowerment.', 'In October 2023, Xiromed LLC announced the U.S. launch of EnilloRing® (etonogestrel/ethinyl estradiol vaginal ring), a generic version of Nuvaring®, further expanding its women’s health portfolio. Developed and manufactured by Laboratorios Leon Pharma SAU in Spain, this product highlights Insud Pharma’s commitment to advanced technologies. EnilloRing® joins Xiromed's range of contraceptive options in the U.S., a market where Nuvaring® and its generics achieved $528 million in sales for the year ending July 2023. Xiromed is known for offering high-quality generics, including injectables and inhalation products, in the U.S. market.'

The high prevalence of STIs within the U.S. is a primary driver in the contraceptive market, as it has been estimated to be over 2.4 million reported cases in 2023. With such growing concern among sexually active individuals, there is an increased demand for dual-protection methods. Public health campaigns and the 2024 STI Prevention Conference, with over 1,200 attendees and 251 poster presentations, indicate that the need for using contraceptives has increased for preventing pregnancyand STIs. Condoms have become the favorite barrier method that is fueling market growth.

Rising consumer demand for safer, natural contraceptive options: A meteoric increase in research and investment in non-hormonal contraceptives was spurred by high consumer demand for alternatives to hormonal contraceptives, coupled with the increasingly alarming side effects and health risks associated with hormonal birth control. Active efforts are being made to develop and test non-hormonal methods such as copper IUDs, fertility awareness-based methods, and barrier options like condoms and diaphragms. This will have a major impact on the future growth of the non-hormonal contraceptive market, as this demand is from safer and more natural alternatives. According to the Guttmacher Institute, 30% of women are interested in non-hormonal methods due to hormonal birth control side effects and health risks, which was reported by a 2021 survey. The increasing interest in non-hormonal contraceptives reflects a growing consumer awareness of the long-term effects of hormonal methods and a larger market shift toward holistic wellness.

U.S. contraceptive market is experiencing steady growth, driven by increasing awareness of reproductive health and the availability of advanced contraceptive options. Our study reveals that the market is segmented into hormonal and non-hormonal methods, with hormonal contraceptives, including oral pills, implants, and IUDs, holding the largest share. The rising preference for long-acting reversible contraceptives (LARCs) is a key trend, as they offer convenience and higher efficacy rates.